TSHA vs. CMPX
TSHA (Taysha Gene Therapies, Inc.) and CMPX (Compass Therapeutics Inc.) are both stocks. Both operate in the Biotechnology industry within the Healthcare sector. Over the past 5 years, TSHA returned -23.39%/yr vs -16.98%/yr for CMPX. At a 0.23 correlation, their price movements are largely independent.
Performance
TSHA vs. CMPX - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, TSHA achieves a 7.09% return, which is significantly higher than CMPX's -60.34% return.
TSHA
- 1D
- 6.13%
- 1M
- -15.13%
- YTD
- 7.09%
- 6M
- 16.40%
- 1Y
- 111.11%
- 3Y*
- 92.17%
- 5Y*
- -23.39%
- 10Y*
- —
CMPX
- 1D
- 1.43%
- 1M
- 9.23%
- YTD
- -60.34%
- 6M
- -61.55%
- 1Y
- -1.84%
- 3Y*
- -11.08%
- 5Y*
- -16.98%
- 10Y*
- —
TSHA vs. CMPX - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
TSHA Taysha Gene Therapies, Inc. | 7.09% | 217.92% | -2.26% | -21.68% | -80.60% | -41.72% |
CMPX Compass Therapeutics Inc. | -60.34% | 270.34% | -7.05% | -68.99% | 58.68% | -62.71% |
Correlation
The correlation between TSHA and CMPX is 0.34, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.34 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.29 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.24 |
Correlation (All Time) Calculated using the full available price history since Apr 6, 2021 | 0.23 |
The correlation between TSHA and CMPX shifts across timeframes, from 0.23 (all time) to 0.34 (1 year), reflecting how their relationship changes across market environments.
Fundamentals
TSHA:
$2.16B
CMPX:
$397.03M
TSHA:
-$0.39
CMPX:
-$0.42
TSHA:
10.19
CMPX:
2.13
TSHA:
$7.47M
CMPX:
$0.00
TSHA:
$6.89M
CMPX:
-$370.00K
TSHA:
-$130.51M
CMPX:
-$72.86M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
TSHA vs. CMPX — Risk / Return Rank
TSHA
CMPX
TSHA vs. CMPX - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Taysha Gene Therapies, Inc. (TSHA) and Compass Therapeutics Inc. (CMPX). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| TSHA | CMPX | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +1.30 | ||
| Sortino ratioReturn per unit of downside risk | +1.78 | ||
| Omega ratioGain probability vs. loss probability | 1.29 | 1.15 | +0.14 |
| Calmar ratioReturn relative to maximum drawdown | 3.59 | -0.02 | +3.61 |
| Martin ratioReturn relative to average drawdown | 7.34 | -0.07 | +7.42 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading charts...
Sharpe Ratios by Period
| TSHA | CMPX | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | 1.28 | -0.02 | +1.30 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | -0.17 | -0.20 | +0.02 |
Sharpe Ratio (All Time)Calculated using the full available price history | -0.17 | -0.27 | +0.10 |
Drawdowns
TSHA vs. CMPX - Drawdown Comparison
The maximum TSHA drawdown since its inception was -98.14%, which is greater than CMPX's maximum drawdown of -90.91%. Use the drawdown chart below to compare losses from any high point for TSHA and CMPX.
Loading charts...
Drawdown Indicators
| TSHA | CMPX | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -98.14% | -90.91% | -7.23% |
Max Drawdown (1Y)Largest decline over 1 year | -31.13% | -75.04% | +43.91% |
Max Drawdown (3Y)Largest decline over 3 years | -72.90% | -76.47% | +3.57% |
Max Drawdown (5Y)Largest decline over 5 years | -97.76% | -85.53% | -12.23% |
Current DrawdownCurrent decline from peak | -81.45% | -75.80% | -5.65% |
Average DrawdownAverage peak-to-trough decline | -76.87% | -65.75% | -11.12% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 15.18% | 25.81% | -10.63% |
Volatility
TSHA vs. CMPX - Volatility Comparison
The current volatility for Taysha Gene Therapies, Inc. (TSHA) is 18.07%, while Compass Therapeutics Inc. (CMPX) has a volatility of 19.20%. This indicates that TSHA experiences smaller price fluctuations and is considered to be less risky than CMPX based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| TSHA | CMPX | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 18.07% | 19.20% | -1.13% |
Volatility (6M)Calculated over the trailing 6-month period | 51.69% | 112.68% | -60.99% |
Volatility (1Y)Calculated over the trailing 1-year period | 87.31% | 94.05% | -6.74% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 136.62% | 87.01% | +49.61% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 130.70% | 88.37% | +42.33% |
Dividends
TSHA vs. CMPX - Dividend Comparison
Neither TSHA nor CMPX has paid dividends to shareholders.
Financials
TSHA vs. CMPX - Financials Comparison
This section allows you to compare key financial metrics between Taysha Gene Therapies, Inc. and Compass Therapeutics Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
Frequently Asked Questions
TSHA and CMPX have a correlation of 0.34, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
CMPX has higher volatility (19.20%) compared to TSHA (18.07%). In terms of maximum drawdown, TSHA dropped -98.14% vs CMPX's -90.91%.
TSHA currently has the higher Sharpe Ratio (1.28 vs -0.02), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for TSHA and CMPX
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer